Discover Our Group:

Berlin-Chemie has been developing, manufacturing and distributing pharmaceutical products for over 130 years and has been a wholly owned subsidiary of the Menarini Group, the leading Italian pharmaceutical company, since 1992. 

Responsibility is a top priority at Berlin-Chemie. We not only make an important contribution to healthcare, but also put our values into practice through various social initiatives.

Discover More about Global Responsibility

From school kits to free meals and medicines, to caring for the environment around the world. In Menarini, being responsible means translating our values into concrete actions that are good for others and good for the planet

Berlin-Chemie – a strong partner. Our many years of experience and the success of joint projects make us the partner of choice. 

Discover More about Global Partnering

Menarini has in-depth know-how in many important therapeutic areas, thanks to many years of excellent market introduction, marketing and sales capabilities as well as expertise in regulatory aspects and market access. Collaboration is the key to great success, and at Menarini, partnership is part of the DNA.

Our holistic and professional health management offers doctors individual counselling, training or workshops, events and lectures on many topics, depending on their needs.

Our Medical Hub acts as a central point of contact for doctors and healthcare professionals. Here you will find all the information about our medications, additional service and training opportunities.

Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material. 

Menarini Blog

Follow Us

We employ professionals with a wide variety of career backgrounds and are employers who care about their staff. Together, we stand for innovation and reliability.

Our Job Portal

Find out about our current vacancies at Berlin-Chemie directly on our career portal.

Menarini Group News

2022 - 03 - 14



Menarini’s novel CoronaMeltVAR test detects SARS CoV-2 and discriminates the potential presence of the Delta, Omicron BA.1 or Omicron BA.2 variants

The sub-variant Omicron 2 (BA.2), similar in some parts to the Omicron variant and in other parts to the Delta variant, is the subject of epidemiological studies and possibly of clinical relevance for the prescription of monoclonal antibodies to COVID-19 patients.

CoronaMeltVAR is a Real Time PCR molecular kit designed to detect positivity to any variant of SARS CoV-2 and simultaneously determine the presence of certain classes of variants. Based on the melting curve analysis principle, this system produces a "profile" or fingerprint of the viral genome, related to the Omicron and Delta variants.

In just 90 minutes, the kit can differentiate the potential presence of the Delta, Omicron BA.1 or Omicron BA.2 variants in a SARS CoV-2 positive sample with a single amplification and subsequent analysis of the melting curve, even on low viral load samples.

This rapid and cost effective pre-screening allows sequencing attention to be focused on samples already classified as suspicious, facilitating the in-depth investigation of the spread and pathogenicity of rare variants in the population such as, at present, the Omicron 2 (BA.2) variant.

All the samples thus classified into categories by the CoronaMeltVAR kit can then be confirmed by sequencing for an accurate definition of the molecular variant.


For more information, please visit CoronaMeltVAR web page  


A.Menarini Diagnosticsthe Human Touch of Technology: more than 45 years dedicated to helping healthcare professionals make safe and sustainable diagnosis, improving the quality of life of people all over the world.
A.Menarini Diagnostics is part of the Menarini Pharmaceutical Group, founded in 1886. Today it is present in 140 countries throughout the world, it counts more than 17,000 employees and has a 2020 turnover of € 3.750 billion.